1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs

Details 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs

1998-09-03

2002-12-10

Qazi, Sabiha (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

C552S653000

Reexamination Certificate

active

06492353

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to 1,3-dihydroxy-20,20-dialkyl-vitamin D
3
analogs, compositions comprising the analogs and methods of treatment of osteoporosis, secondary hyperparathyroidism, cancer and autoimmune diseases using such analogs.
2. Description of Related Art
a. Osteoporosis
Osteoporosis is the most common form of metabolic bone disease and may be considered the symptomatic, fracture stage of bone loss (osteopenia). Although osteoporosis may occur secondary to a number of underlying diseases, 90% of all cases appear to be idiopathic. Postmenopausal women are at risk for idiopathic osteoporosis (postmenopausal or Type I osteoporosis); another particularly high risk group for idiopathic osteoporosis is the elderly of either sex (senile or Type II osteoporosis). Osteoporosis has also been related to corticosteroid use, immobilization or extended bed rest, alcoholism, diabetes, gonadotoxic chemotherapy, hyperprolactinemia, anorexia nervosa, primary and secondary amenorrhea, transplant immunosuppression, and oophorectomy. Postmenopausal osteoporosis is characterized by fractures of the spine, while femoral neck fractures are the dominant features of senile osteoporosis.
The mechanism by which bone is lost in osteoporotics is believed to involve an imbalance in the process by which the skeleton renews itself. This process has been termed bone remodeling. It occurs in a series of discrete pockets of activity. These pockets appear spontaneously within the bone matrix on a given bone surface as a site of bone resorption. Osteoclasts (bone dissolving or resorbing cells) are responsible for the resorption of a portion of bone of generally constant dimension. This resorption process is followed by the appearance of osteoblasts (bone forming cells) which then refill with new bone the cavity left by the osteoclasts.
In a healthy adult subject, osteoblasts and osteoclasts function so that bone formation and bone resorption are in balance. However, in osteoporotics an imbalance in the bone remodeling process develops which results in bone being replaced at a slower rate than it is being lost. Although this imbalance occurs to some extent in most individuals as they age, it is much more severe and occurs at a younger age in postmenopausal osteoporotics, following oophorectomy, or in iatrogenic situations such as those resulting from corticosteroid therapy or the immunosuppression practiced in organ transplantation.
Various approaches have been suggested for increasing bone mass in humans afflicted with osteoporosis, including administration of androgens, fluoride salts, and parathyroid hormone and modified versions of parathyroid hormone. It has also been suggested that bisphosphonates, calcitonin, calcium, 1,25-dihydroxy vitamin D
3
and some of its analogs, and/or estrogens, alone or in combination, may be useful for preserving existing bone mass.
Vitamin D
3
is a critical element in the metabolism of calcium, promoting intestinal absorption of calcium and phosphorus, maintaining adequate serum levels of calcium and phosphorus, and stimulating flux of calcium into and out of bone. The D vitamins are hydroxylated in vivo, with the resulting 1&agr;,25-dihydroxy metabolite being the active material. Animal studies with 1,25-(OH)
2
vitamin D
3
have suggested bone anabolic activity. Aerssens et al., in
Calcif Tissue Int
, 55:443-450 (1994), reported upon the effect of 1&agr;-hydroxy vitamin D
3
on bone strength and composition in growing rats with and without corticosteroid treatment. However, human usage is restricted to antiresorption due to the poor therapeutic ratio (hypercalciuria and hypercalcemia as well as nephrotoxicity).
Dechant and Goa, in “Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis”, Drugs Aging [NEW ZEALAND 5 (4): 300-17 (1994)], reported that 1,25-dihydroxy vitamin D
3
(calcitriol) has shown efficacy in the treatment of postmenopausal osteoporosis (and promise in corticosteroid-induced osteoporosis) based upon a clinical trial in 622 women with postmenopausal osteoporosis. Patients with mild to moderate disease (but not those with more severe disease) who received calcitriol (0.25 microgram twice daily) had a significant 3-fold lower rate of new vertebral fractures after 3 years of treatment compared with patients receiving elemental calcium 1000 mg/day. In patients commencing long term treatment with prednisone or prednisolone, calcitriol 0.5 to 1.0 micrograms/day plus calcium 1000 mg/day, administered with or without intranasal calcitonin 400 IU/day, prevented steroid-induced bone loss. Overall, calcitriol was well tolerated. At recommended dosages hypercalcaemia was infrequent and mild, generally responding to reductions in calcium intake and/or calcitriol dosage. The narrow therapeutic window of calcitriol required that its use be adequately supervised, with periodic monitoring of serum calcium and creatinine levels. This study clearly identifies the key limitation of calcitriol therapy as the close proximity of therapeutic and toxic doses.
This invention provides novel vitamin D
3
derivatives which have more favorable therapeutic doses.
b. Cancer
Epidemiologic studies have correlated sun or UV light exposure with a lower incidence of a variety of malignancies, including breast, colon and prostate cancer. Evidence from receptor studies demonstrates that besides the classic target organs, such as intestine, kidney and bone, vitamin D receptors (VDR) are present on a wide variety of human normal and cancer cell lines and fresh tissue. Growth inhibition with vitamin D or 1,25-dihydroxycholecalciferol does not always translate into potential therapeutic efficacy in vivo. Early in vivo studies have focused on the anti-proliferative effects of 1,25-dihydroxycholecalciferol and its analogues in murine leukemia model systems where 1,25-dihydroxycholecalciferol has been shown to induce not only an anti-proliferative effect, but also a differentiating effect. Therapeutic efficacy in vivo has its limitations due to the hypercalcemia observed with high dose treatment of the parent 1,25-dihydroxycholecalciferol. As a result, a number of analogues have been developed that produce significant anti-tumor effects without hypercalcemia.
Steinmeyer et al in U.S. Pat. No. 5,585,368 discloses 1&agr;-25-dihydroxy-20-disubstituted vitamin D
3
analogs for the treatment of hyperproliferative disorders of the skin, malignant tumors such as leukemia, colon and breast cancers, autoimmune diseases such as diabetes and for the treatment of sebaceous gland diseases. Danielsson, C. et al in
J. Cell Biochem
., 63, No. 2, 199-206 (1996) disclose 20-methyl analogues of 1,25-dihydroxy vitamin D
3
, including 1&agr;-25-dihydroxy-20-methyl-23(E)-ene-cholecalciferol for the treatment of hyperproliferative disorders. This invention provides novel vitamin D
3
derivatives for the treatment of hyperproliferative disorders of the skin, malignant tumors such as leukemia, colon and breast cancers, autoimmune diseases such as diabetes and for the treatment of sebaceous gland diseases which have more favorable therapeutic ratios or margins.
c. Hyperparathyroidism
Secondary hyperparathyroidism is routine in patients with chronic renal failure. It is established that the reduction of renal 1,25(OH)
2
vitamin D
3
(calcitriol) synthesis is one of the principal mechanisms leading to the secondary hyperparathyroidism in these patients and it has been shown that calcitriol possesses direct suppressive action on PTH synthesis. Therefore, administration of calcitriol has been recommended for the treatment of secondary hyperparathyroidism in these patients. However, as described above, calcitriol has potent hypercalcemic effects giving it a narrow therapeutic window which limits its usage, especially at high doses. It would therefore be desirable to have an alternative means of treating hyperparathyroidism and repleting circulating vitamin D
3
activity without

Affiliated with

Also associated with

Rating

1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2922827